Gastric ulcer Medical Services in China

A gastric ulcer is a circumscribed mucosal defect in the stomach lining that extends through the muscularis mucosae into the submucosa or deeper layers. Unlike superficial erosions, gastric ulcers involve structural disruption of the gastric wall and carry higher risks of complications including bleeding, perforation, gastric outlet obstruction, and malignant transformation. Pathogenesis centers on an imbalance between aggressive factors—primarily Helicobacter pylori infection (present in 70–90% of cases), nonsteroidal anti-inflammatory drug (NSAID) use, excessive gastric acid secretion, and smoking—and defensive mechanisms such as mucus-bicarbonate barrier integrity, mucosal blood flow, prostaglandin synthesis, and epithelial restitution. H. pylori induces chronic active gastritis, disrupts tight junctions, increases IL-8-mediated neutrophil infiltration, and upregulates acid production via ghrelin and histamine pathways. NSAIDs inhibit cyclooxygenase-1 (COX-1), reducing protective prostaglandins (PGE2 and PGI2) critical for mucus secretion and microvascular perfusion. Epidemiologically, gastric ulcers affect approximately 5–10% of the global population during their lifetime, with incidence rising sharply after age 50. In China, prevalence is estimated at 4.5–6.2% among adults undergoing upper endoscopy for dyspepsia, with male-to-female ratio of ~1.8:1. Key modifiable risk factors include chronic NSAID or low-dose aspirin use, smoking (doubles ulcer risk and impairs healing), heavy alcohol consumption, psychological stress (via vagal hyperactivity and impaired mucosal defense), and untreated H. pylori infection. Non-modifiable risks include advanced age, prior peptic ulcer disease, and genetic polymorphisms affecting interleukin-1β and TNF-α expression. Gastric ulcers significantly impair quality of life: patients commonly report recurrent epigastric pain (often burning or gnawing, worsened by fasting and relieved by food/antacids), early satiety, nausea, postprandial bloating, and fear of eating—leading to weight loss, sleep disruption, work absenteeism, and heightened anxiety about malignancy. Untreated or recurrent ulcers correlate with reduced physical functioning scores (SF-36), increased depression prevalence (up to 32%), and diminished social participation. With timely diagnosis—typically via esophagogastroduodenoscopy (EGD) with biopsy—and evidence-based therapy, >90% of uncomplicated ulcers heal within 6–8 weeks, and recurrence rates drop below 10% with sustained H. pylori eradication and NSAID de-escalation.

Gastric ulcers—circumscribed mucosal defects extending through the muscularis mucosae into the gastric submucosa—are a common yet potentially serious manifestation of gastroduodenal pathology. Management in gastroenterology departments prioritizes ulcer healing, symptom relief, complication prevention (e.g., hemorrhage, perforation, obstruction, or malignancy), and eradication of underlying etiologies—most notably Helicobacter pylori infection and nonsteroidal anti-inflammatory drug (NSAID) use. Treatment is stratified into conservative (non-invasive), pharmacologic, and surgical modalities, with individualized decision-making guided by endoscopic findings, patient comorbidities, ulcer size and location, bleeding stigmata, and response to initial therapy.

Conservative treatment forms the cornerstone for most uncomplicated gastric ulcers and emphasizes lifestyle modification and risk factor mitigation. Patients are advised to discontinue all NSAIDs—including low-dose aspirin—unless clinically indispensable (e.g., secondary cardiovascular prevention), in which case gastroprotection with proton pump inhibitors (PPIs) must be co-administered. Smoking cessation is strongly mandated, as nicotine impairs mucosal blood flow, reduces bicarbonate secretion, and delays ulcer healing. Alcohol intake should be restricted or eliminated due to its direct mucosal irritant effect and synergistic interaction with H. pylori and NSAIDs. Dietary counseling focuses on symptom-guided adjustments rather than rigid restrictions; while spicy, acidic, or caffeinated foods do not cause ulcers, they may exacerbate dyspepsia in sensitive individuals. Stress reduction techniques—including cognitive behavioral therapy and mindfulness-based interventions—are recommended adjunctively, particularly in patients with functional dyspepsia overlapping with ulcer symptoms, though psychosocial stress alone is not a primary ulcerogenic factor.

Pharmacotherapy remains the mainstay of medical management. First-line treatment centers on high-dose PPIs (e.g., esomeprazole 40 mg once daily or rabeprazole 20 mg twice daily) administered for 8 weeks to achieve optimal acid suppression (intragastric pH > 4 for ≥16 hours/day), which promotes mucosal restitution and inhibits pepsin activity. For H. pylori-positive ulcers—which account for approximately 70–80% of idiopathic cases—concomitant eradication therapy is mandatory. Current Chinese and international guidelines endorse bismuth quadruple therapy as first-line: a PPI plus bismuth subsalicylate (240 mg twice daily), tetracycline (500 mg four times daily), and metronidazole (400 mg four times daily) for 10–14 days. This regimen achieves >90% eradication rates in China, where clarithromycin resistance exceeds 25%, rendering standard triple therapy obsolete. In penicillin-allergic patients, high-dose dual therapy (PPI + amoxicillin 1 g three times daily) is an emerging alternative supported by recent multicenter trials in China. For NSAID-induced ulcers without H. pylori, PPI continuation beyond acute healing (typically 6 months) is indicated if NSAID rechallenge is unavoidable. Misoprostol (a prostaglandin E1 analog) may be considered in select high-risk patients intolerant to PPIs, though its side-effect profile (diarrhea, uterine cramping) limits adherence.

Surgical intervention is now rare (<1% of cases) but remains critical for life-threatening complications. Indications include hemodynamically unstable upper gastrointestinal bleeding refractory to endoscopic hemostasis (e.g., visible vessel, spurting), free perforation with peritonitis, gastric outlet obstruction unresponsive to medical decompression and dilation, or suspicion of malignancy on biopsy or imaging. Laparoscopic wedge resection or partial gastrectomy (Billroth I or II) is preferred over open surgery, offering reduced postoperative pain, shorter hospital stays (median 4–6 days), and faster return to oral intake. In China, robotic-assisted gastrectomy is increasingly performed in tertiary centers for complex or recurrent ulcers, leveraging enhanced dexterity and 3D visualization. Surgery also plays a diagnostic role when endoscopic biopsies are inconclusive but clinical suspicion for gastric adenocarcinoma remains high—particularly in ulcers >2 cm, irregular margins, or those failing to heal after 12 weeks of optimized medical therapy.

Treatment advantages in China stem from integrated, protocol-driven care across tiered healthcare institutions. National consensus guidelines (e.g., the 2023 Chinese Society of Gastroenterology Ulcer Management Recommendations) standardize H. pylori testing (stool antigen, urea breath test, or rapid urease test during endoscopy) and empiric regimens based on local resistance patterns. High-volume endoscopy centers perform >500 therapeutic upper GI endoscopies annually, ensuring expertise in advanced hemostatic techniques (e.g., hemoclip placement, epinephrine injection with thermal coagulation). Real-time tele-endoscopy networks connect rural hospitals with provincial experts for urgent second opinions. Moreover, China’s national essential medicines list ensures universal access to generic PPIs and bismuth compounds at minimal cost, improving adherence. Pharmacovigilance systems monitor regional antibiotic resistance trends, enabling dynamic regimen updates—contributing to sustained >90% eradication success in compliant patients.

Recovery advice emphasizes structured follow-up and long-term vigilance. All patients require repeat upper endoscopy at 8–12 weeks post-treatment to confirm complete healing and exclude malignancy—mandatory even in H. pylori-negative or NSAID-related ulcers. H. pylori eradication must be confirmed via urea breath test or stool antigen test ≥4 weeks after therapy completion and off PPIs for ≥2 weeks. Patients should avoid NSAIDs for at least 8 weeks post-healing; if reinstitution is necessary, concurrent PPI prophylaxis is non-negotiable. Annual symptom review is advised for those with recurrent ulcer history or chronic NSAID use. Nutritional support includes small, frequent meals rich in zinc, vitamin A, and antioxidants (e.g., berries, leafy greens), which support epithelial repair. Finally, patients must recognize red-flag symptoms—hematemesis, melena, persistent vomiting, or unrelenting epigastric pain—and seek immediate evaluation, as delayed presentation increases mortality in complicated disease. With comprehensive, evidence-based, and accessible care, gastric ulcer prognosis in modern gastroenterology practice is excellent, with >95% healing rates and <2% recurrence at one year when risk factors are adequately controlled.